Sangamo Biosciences (SGMO) : Fic Capital Inc reduced its stake in Sangamo Biosciences by 0.01% during the most recent quarter end. The investment management company now holds a total of 862,489 shares of Sangamo Biosciences which is valued at $3,803,576 after selling 55 shares in Sangamo Biosciences , the firm said in a disclosure report filed with the SEC on Aug 11, 2016.Sangamo Biosciences makes up approximately 1.72% of Fic Capital Inc’s portfolio.
Other Hedge Funds, Including , Vanguard Group Inc boosted its stake in SGMO in the latest quarter, The investment management firm added 234,286 additional shares and now holds a total of 2,694,393 shares of Sangamo Biosciences which is valued at $11,882,273.Blair William Coil reduced its stake in SGMO by selling 5,500 shares or 34.59% in the most recent quarter. The Hedge Fund company now holds 10,400 shares of SGMO which is valued at $46,176.Columbus Circle Investors boosted its stake in SGMO in the latest quarter, The investment management firm added 151,487 additional shares and now holds a total of 293,483 shares of Sangamo Biosciences which is valued at $2,007,424. Sangamo Biosciences makes up approx 0.02% of Columbus Circle Investors’s portfolio.
Sangamo Biosciences closed down -0.02 points or -0.45% at $4.4 with 4,95,802 shares getting traded on Tuesday. Post opening the session at $4.45, the shares hit an intraday low of $4.391 and an intraday high of $4.495 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
On the company’s financial health, Sangamo Biosciences reported $-0.38 EPS for the quarter, missing the analyst consensus estimate by $ -0.14 based on the information available during the earnings call on Aug 3, 2016. Analyst had a consensus of $-0.24. The company had revenue of $3.70 million for the quarter, compared to analysts expectations of $5.55 million. The company’s revenue was down -56.0 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.17 EPS.
Sangamo Biosciences Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the research development and commercialization of engineered DNA-binding proteins as therapeutic products. The main focus for the Company is the development of novel human therapeutics and it is building a pipeline of ZFP Therapeutics. The Company’s lead ZFP Therapeutic SB-728-T a ZFN-modified autologous T-cell product is under development for the treatment of HIV/AIDS. The Company’s clinical stage programs also include SB-728-HSPC for the treatment of HIV/AIDS SB-BCLmR-HSPC to treat Beta-thalassemia major and CERE-110 for the treatment of Alzheimers disease. Its pre-clinical products include SB-913 for the treatment of Hunter Syndrome and SB-318 for the treatment of Hurler Syndrome.